165 related articles for article (PubMed ID: 16127777)
1. Clinical significance of p16 protein expression loss and aberrant p53 protein expression in pancreatic cancer.
Jeong J; Park YN; Park JS; Yoon DS; Chi HS; Kim BR
Yonsei Med J; 2005 Aug; 46(4):519-25. PubMed ID: 16127777
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
[TBL] [Abstract][Full Text] [Related]
3. Aberrant p16INK4 expression related to clinical stage and prognosis in patients with pancreatic cancer.
Naka T; Kobayashi M; Ashida K; Toyota N; Kaneko T; Kaibara N
Int J Oncol; 1998 May; 12(5):1111-6. PubMed ID: 9538137
[TBL] [Abstract][Full Text] [Related]
4. Prognostic prediction of the immunohistochemical expression of p53 and p16 in resected non-small cell lung cancer.
Cheng YL; Lee SC; Harn HJ; Chen CJ; Chang YC; Chen JC; Yu CP
Eur J Cardiothorac Surg; 2003 Feb; 23(2):221-8. PubMed ID: 12559346
[TBL] [Abstract][Full Text] [Related]
5. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
[TBL] [Abstract][Full Text] [Related]
6. DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma.
Biankin AV; Morey AL; Lee CS; Kench JG; Biankin SA; Hook HC; Head DR; Hugh TB; Sutherland RL; Henshall SM
J Clin Oncol; 2002 Dec; 20(23):4531-42. PubMed ID: 12454109
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous deregulation of p16 and cyclin D1 genes in pancreatic ductal adenocarcinoma: a combined immunohistochemistry and image analysis study based on tissue microarrays.
Tsiambas E; Karameris A; Gourgiotis S; Salemis N; Athanassiou AE; Karakitsos P; Papalois A; Merikas E; Kosmidis P; Patsouris E
J BUON; 2007; 12(2):261-7. PubMed ID: 17600882
[TBL] [Abstract][Full Text] [Related]
8. Frequent loss of p16 expression and its correlation with clinicopathological parameters in pancreatic carcinoma.
Hu YX; Watanabe H; Ohtsubo K; Yamaguchi Y; Ha A; Okai T; Sawabu N
Clin Cancer Res; 1997 Sep; 3(9):1473-7. PubMed ID: 9815833
[TBL] [Abstract][Full Text] [Related]
9. The expression of p53, p16 proteins and prevalence of apoptosis in oral squamous cell carcinoma. Correlation with mode of invasion grading system.
Tokman B; Gultekin SE; Sezer C; Alpar R
Saudi Med J; 2004 Dec; 25(12):1922-30. PubMed ID: 15711668
[TBL] [Abstract][Full Text] [Related]
10. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
Tzai TS; Tsai YS; Chow NH
Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
[TBL] [Abstract][Full Text] [Related]
11. An immunohistochemical study of p16, pRb, p21 and p53 proteins in human esophageal cancers.
Kato H; Yoshikawa M; Fukai Y; Tajima K; Masuda N; Tsukada K; Kuwano H; Nakajima T
Anticancer Res; 2000; 20(1A):345-9. PubMed ID: 10769678
[TBL] [Abstract][Full Text] [Related]
12. Analysis of p53, p16(INK4a), pRb and Cyclin D1 expression and human papillomavirus in primary ovarian serous carcinomas.
Bilyk OO; Pande NT; Buchynska LG
Exp Oncol; 2011 Sep; 33(3):150-6. PubMed ID: 21956468
[TBL] [Abstract][Full Text] [Related]
13. Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence.
Ito Y; Matsuura N; Sakon M; Miyoshi E; Noda K; Takeda T; Umeshita K; Nagano H; Nakamori S; Dono K; Tsujimoto M; Nakahara M; Nakao K; Taniguchi N; Monden M
Hepatology; 1999 Jul; 30(1):90-9. PubMed ID: 10385644
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome and expression of mutant P53, P16, and Smad4 in lung adenocarcinoma: a prospective study.
Bian C; Li Z; Xu Y; Wang J; Xu L; Shen H
World J Surg Oncol; 2015 Mar; 13():128. PubMed ID: 25890228
[TBL] [Abstract][Full Text] [Related]
15. Abnormalities of tumor suppressor gene p16 in pancreatic carcinoma: immunohistochemical and genetic findings compared with clinicopathological parameters.
Ohtsubo K; Watanabe H; Yamaguchi Y; Hu YX; Motoo Y; Okai T; Sawabu N
J Gastroenterol; 2003; 38(7):663-71. PubMed ID: 12898359
[TBL] [Abstract][Full Text] [Related]
16. [Detection of expression of p53, p16, and cyclooxygenase 2 in pancreatic cancer by tissue microarray and correlation among these three genes].
Li YM; Yu ZH; Li L; Xu P; Li L; Zhang BF; Fang J; Zhou Q; Hu Y; Gao HJ
Zhonghua Yi Xue Za Zhi; 2006 Apr; 86(14):939-42. PubMed ID: 16759529
[TBL] [Abstract][Full Text] [Related]
17. [Expression of DPC4/Smad4, p21wafI, and p16 in human pancreatic cancer].
Gu LJ; Chen J; Lu ZH; Li L; Zhou WX; Luo YF
Ai Zheng; 2002 Feb; 21(2):132-7. PubMed ID: 12479060
[TBL] [Abstract][Full Text] [Related]
18. Expression and clinical significance of the G1-S modulators in carcinoma of the extrahepatic bile duct.
Ito Y; Takeda T; Sakon M; Monden M; Tsujimoto M; Matsuura N
Anticancer Res; 2000; 20(1A):337-44. PubMed ID: 10769677
[TBL] [Abstract][Full Text] [Related]
19. [Expression of PTEN, p16, p21, and p53 proteins in lung cancer using tissue microarray and their clinical significance].
Liao XB; Hu DX; Zhou XM; Yu FL; Yuan YC; Chen MJ
Ai Zheng; 2004 Mar; 23(3):334-8. PubMed ID: 15025970
[TBL] [Abstract][Full Text] [Related]
20. Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas.
Engelsen IB; Stefansson I; Akslen LA; Salvesen HB
Am J Obstet Gynecol; 2006 Oct; 195(4):979-86. PubMed ID: 16677592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
